Roig, Marta Bofill
Krotka, Pavla
Burman, Carl-Fredrik
Glimm, Ekkehard
Gold, Stefan M.
Hees, Katharina
Jacko, Peter
Koenig, Franz
Magirr, Dominic
Mesenbrink, Peter
Viele, Kert
Posch, Martin
Funding for this research was provided by:
Innovative Medicines Initiative (853966, 853966, 853966, 853966, 853966, 853966, 853966, 853966, 853966, 853966, 853966, 853966)
Article History
Received: 10 December 2021
Accepted: 12 July 2022
First Online: 15 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: Carl-Fredrik Burman is an employee and shareholder of AstraZeneca. Dominic Magirr declares a competing interest as an employee of Novartis Pharma AG. Peter Mesenbrink is an employee of Novartis Pharmaceuticals Corporation and owns both restricted and unrestricted shares of stock in Novartis. Peter Jacko and Kert Viele are employees of Berry Consultants, a consulting company specializing in the design of Bayesian and adaptive clinical trials. The rest of the authors declare that they have no competing interests regarding the content of this article.